This is a working overview of Synaptogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-27. Anything still debated is marked as such rather than presented as settled.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
| Property | Value | Notes |
|---|---|---|
| Common name | Dihexa | Shorthand used in research literature and supplier catalogs. |
| CAS Registry Number | 1401708-83-5 | Identifier assigned to the synthetic peptide. |
| Molecular formula | C27H44N4O5 | Reported formula; verify with a certificate of analysis. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Typical storage | −20 °C or below, desiccated | Common condition for peptide stability. |
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
About one in ten marijuana users developed a substance use disorder, and those who use it before the age of 18 are more likely to suffer from it. Marijuana use in the United States is three times above the global average, but in line with other Western democracies. Forty-four percent of American high-school seniors have tried the drug at least once, and the typical age of first-use is 16, similar to the typical age of first-use for alcohol but lower than the first-use age for other illicit drugs.
=== AIDS === It seems that Th22 cells could play a protective role in patients with AIDS. CCR5 and α4β7 molecules expressed by Th22 cells were able to bind to the circulating HIV receptor, and thus via interleukin-22 (IL-22) production protect against intestinal epithelial damage, leading to a mechanism of resistance against HIV-induced destruction of epithelial cell integrity.
== Related substrates == In some species, the kynurenine pathway also processes 6-bromotryptophan, leading to the analogous series of brominated metabolites. These and subsequent derivatives are believed to be responsible for the biofluorescence observed in the skin of the swell shark and the chain catshark.
== Etymology == Samaale, the last common ancestor of several Somali clans, is generally regarded as the source of the ethnonym Somali. Another theory is that the name is derived from the words soo and maal, which together mean "go" and "milk". This interpretation varies depending on region, with northern Somalis believing it means "camel's milk," and southern Somalis using the transliteration "sa maal", which refers to cow's milk. This is a reference to the pastoralism of the Somali people. Another proposed etymology is that the term Somali is derived from the Arabic ذوو مال, transliterated as dhawu māl and meaning "wealthy", again referring to Somali riches in livestock. The first written reference of the sobriquet Somali dates back to the early 15th century AD during the reign of Ethiopian Emperor Yeshaq I, who had one of his court officials compose a hymn celebrating a military victory over the Sultanate of Ifat. Simur was also an ancient Harari alias for the Somali people.
Louisville hotspot (23) 53°36′S 140°36′W, w= 1 az= 316° ±5° rate= 67 ±5 mm/yr Possibly related to the Ontong Java Plateau (125–120 Ma). Foundation hotspot/Ngatemato seamounts (57) 37°42′S 111°06′W, w= 1 az= 292° ±3° rate= 80 ±6 mm/yr Macdonald hotspot (24) 29°00′S 140°18′W, w= 1 az= 289° ±6° rate= 105 ±10 mm/yr North Austral/President Thiers (President Thiers Bank, 58) 25°36′S 143°18′W, w= (1.0) az= 293° ± 3° rate= 75 ±15 mm/yr Arago hotspot (Arago Seamount, 59) 23°24′S 150°42′W, w= 1 az= 296° ±4° rate= 120 ±20 mm/yr Maria/Southern Cook hotspot (Îles Maria, 60) 20°12′S 153°48′W, w= 0.8 az= 300° ±4° Samoa hotspot (35) 14°30′S 168°12′W, w= 0.8 az= 285°±5° rate= 95 ±20 mm/yr Crough hotspot (Crough Seamount, 61) 26°54′S 114°36′W, w= 0.8 az= 284° ± 2° Pitcairn hotspot (31) 25°24′S 129°18′W, w= 1 az= 293° ±3° rate= 90 ±15 mm/yr Society/Tahiti hotspot (38) 18°12′S 148°24′W, w= 0.8 az= 295°±5° rate= 109 ±10 mm/yr Marquesas hotspot (26) 10°30′S 139°00′W, w= 0.5 az= 319° ±8° rate= 93 ±7 mm/yr Caroline hotspot (4) 4°48′N 164°24′E, w= 1 az= 289° ±4° rate= 135 ±20 mm/yr Hawaii hotspot (12) 19°00′N 155°12′W, w= 1 az= 304° ±3° rate= 92 ±3 mm/yr Socorro/Revillagigedos hotspot (37) 19°00′N 111°00′W Guadalupe hotspot (11) 27°42′N 114°30′W, w= 0.8 az= 292° ±5° rate= 80 ±10 mm/yr Cobb hotspot (5) 46°00′N 130°06′W, w= 1 az= 321° ±5° rate= 43 ±3 mm/yr Bowie/Pratt-Welker hotspot (3) 53°00′N 134°48′W, w= 0.8 az= 306° ±4° rate= 40 ±20 mm/yr
Sources: en.wikipedia.org
=== Research in Utah === Research in the Kopeček Biomedical Polymers Laboratory focuses on: a) Macromolecular therapeutics with emphasis on combination chemotherapy and immunotherapy; b) Macromolecular therapeutics for brain delivery; c) Drug-free macromolecular therapeutics – a new paradigm in nanomedicine where apoptosis is initiated by biorecognition of nanoconjugates at the cell surface and receptor crosslinking; no low molecular weight drug is needed.
This has reduced the risk of occupationally induced cancer from radon, although health issues may persist for those who are currently employed in affected mines and for those who have been employed in them in the past. As the relative risk for miners has decreased, so has the ability to detect excess risks among that population.
The G protein's α subunit, together with the bound GTP, can then dissociate from the β and γ subunits to further affect intracellular signaling proteins or target functional proteins directly depending on the α subunit type (Gαs, Gαi/o, Gαq/11, Gα12/13). G protein-coupled receptors are an important drug target and approximately 34% of all Food and Drug Administration (FDA) approved drugs target 108 members of this family. The global sales volume for these drugs is estimated to be 180 billion US dollars as of 2018. It is estimated that GPCRs are targets for about 50% of drugs currently on the market, mainly due to their involvement in signaling pathways related to many diseases i.e. mental, metabolic including endocrinological disorders, immunological including viral infections, cardiovascular, inflammatory, senses disorders, and cancer. The long ago discovered association between GPCRs and many endogenous and exogenous substances, resulting in e.g. analgesia, is another dynamically developing field of pharmaceutical research.
== Honors == Foreign Honorary Member of the American Academy of Arts and Sciences (1832) The Moon crater Legendre is named after him. Main-belt asteroid 26950 Legendre is named after him. Legendre is one of the 72 prominent French scientists who were commemorated on plaques at the first stage of the Eiffel Tower when it first opened. A street in Paris' 17th Arrondissement is named after him.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.
It is produced by chemical synthesis, not extracted from plants or animals. Its design is based on a naturally occurring peptide fragment. Suppliers sell it as a research chemical.
No, dihexa is a modified analog of angiotensin IV. The two share a structural relationship but differ in chemical details. Research on one does not automatically apply to the other.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.